Be part of the knowledge.™

Pathology and Laboratory Medicine

84

LikeLikedUnlike

Episodes 16-30 of 52

Emerging targeted therapy combination strategies in genitourinary malignancies
MinuteCE®
Emerging targeted therapy combination strategies in genitourinary malignancies
- Ignacio Duran, MD
  Peer
1.25 program credits
Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
MinuteCE®
Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
- Ignacio Duran, MD
  Peer
- Wenxin Xu, MD
  Peer
1.25 program credits
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
MinuteCE®
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
- Ignacio Duran, MD
  Peer
- Sandy Srinivas, MD
  Peer
1.25 program credits
Digesting IgG4-RD: An Interactive, Multidisciplinary Case Conference
CME/CE Broadcast Replay
Digesting IgG4-RD: An Interactive, Multidisciplinary Case Conference
- John H. Stone, MD, MPH
  Peer
- Yoh Zen, MD, PhD, FRCPath
  Peer
- Avinash Kambadakone-Ramesh, MD, DNB, FRCR
  Peer
- J. Matthias Löhr, MD
  Peer
1.00 credits
The Evolving Role of MET TKIs in NSCLC
CME/CE
The Evolving Role of MET TKIs in NSCLC
- Gilberto de Lima Lopes, Jr, MD, MBA, FASCO
  Peer
- Jyoti Patel, MD
  Peer
0.75 credits
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
MinuteCE®
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
advertisement
Interprofessional Coordination of Adverse Event Management
MinuteCE®
Interprofessional Coordination of Adverse Event Management
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Recent updates from adjuvant trials in HR+/HER2- EBC
MinuteCE®
Recent updates from adjuvant trials in HR+/HER2- EBC
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Maximizing Adherence and Persistence via Patient Engagement
MinuteCE®
Maximizing Adherence and Persistence via Patient Engagement
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
MinuteCE®
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
MinuteCE®
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
MinuteCE®
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
advertisement
MinuteCE®
Precision Timing: Unveiling the Impact of CDK4/6 Inhibition in Early HR+/HER2- Breast Cancer
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 credits 10 episodes
Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
MinuteCE®
Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Treatment Intensification in HR+/HER2- EBC: Who and When?
MinuteCE®
Treatment Intensification in HR+/HER2- EBC: Who and When?
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits

Program Chapters

Segment Chapters

Playlist:

Recommended